Skip to main content

MOPETT Trial (Multicenter Observational Study of Pulmonary Embolism Thrombolysis)-2013

 MOPETT trial (Multicenter Observational Study of Pulmonary Embolism Thrombolysis) was a randomized controlled trial that evaluated the efficacy and safety of low-dose thrombolysis in patients with acute intermediate-risk pulmonary embolism (PE). 

The trial included 121 patients who were randomly assigned to receive either low-dose alteplase (50 mg) or low-dose heparin plus placebo. 

The primary endpoint of the trial was the development of pulmonary hypertension at 28 months. The secondary endpoints were recurrent PE at 28 months and major bleeding events. 

The results of the trial showed that low-dose alteplase significantly reduced the risk of developing pulmonary hypertension at 28 months compared to low-dose heparin plus placebo (28% vs. 56%).

There was no significant difference between the two groups in the risk of recurrent PE or major bleeding events. 



The MOPETT trial provides evidence that low-dose thrombolysis is an effective and safe treatment option for patients with acute intermediate-risk PE.

Key findings of the MOPETT Trial included: 

1.    Reduced right ventricular strain: The trial showed that catheter-directed thrombolysis with alteplase significantly reduced right ventricular strain, which is a common complication of acute PE and can lead to poor outcomes. 

2.    Improved hemodynamics: Patients who received thrombolysis showed better improvement in their hemodynamic status compared to those treated with anticoagulation alone. 

3.    No significant difference in major bleeding events: The trial found that while thrombolysis increased the risk of minor bleeding events, there was no significant increase in major bleeding events when compared to anticoagulation therapy alone. 

4.    Suggested benefit for select patients: The results suggested that catheter-directed thrombolysis with alteplase may be particularly beneficial for a subset of patients with acute PE who have significant right ventricular strain and hemodynamic instability.

5.    The trial also suggests that low-dose thrombolysis may be particularly beneficial in preventing the development of pulmonary hypertension, a serious complication of PE. 

Here is a summary of the key findings of the MOPETT trial: Low-dose alteplase (50 mg) significantly reduced the risk of developing pulmonary hypertension at 28 months compared to low-dose heparin plus placebo (28% vs. 56%). There was no significant difference between the two groups in the risk of recurrent PE or major bleeding events. Low-dose thrombolysis is an effective and safe treatment option for patients with acute intermediate-risk PE. Low-dose thrombolysis may be particularly beneficial in preventing the development of pulmonary hypertension. 

It is important to note that the MOPETT trial was a small study, and further research is needed to confirm these findings. However, the results of the MOPETT trial provide promising evidence that low-dose thrombolysis may be a valuable treatment option for patients with acute intermediate-risk PE.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Various Methods of Shoulder Joint Reduction

  Shoulder joint dislocation can be reduced by a lot of explained maneuvers. Its better to learn them through some good videos from open source (YouTube and Vimeo) rather than memorizing  The various maneuvers for the reduction of a Dislocated Shoulder Joint are     1. Kochers Maneuver     2. FARES (Fast Reliable and Safe Technique)     3. Hennepin Technique (External Rotation Technique)     4. Milch Technique     5. Stimsons Technique (Gravitational Weight)     6. Hippodratic and Modified Hippocratic Technique     7. Cunningham Technique Kochers Maneuver Adduction-ExtRotation-Flexion-Internal Rotation The process must be very slow and its better to give some muscle relaxant and analgesic prior to the procedure. Cunningham Technique https://www.youtube.com/watch?v=HGIjEEg_PQQ FARES (FAst, REliable and Safe Technique) Small occilating movements while in extension and external rotation. Gradually this is incre...
Post a Comment
Read more

Recent Trials on Balanced Crystalloid Solutions vs. Conventional Intravenous Fluids

Intravenous (IV) fluids are a cornerstone of modern medicine, used extensively in hospitals for resuscitation, maintenance, and replacement therapy. Normal saline (0.9% sodium chloride) has been the most commonly used IV fluid worldwide for decades. However, recent research has raised concerns about its potential adverse effects, particularly its high chloride content, which can lead to hyperchloremic acidosis and kidney injury.  In response, balanced crystalloid solutions, such as lactated Ringer's and Plasma-Lyte, have gained attention as potentially safer alternatives. This article explores the findings of recent trials comparing balanced crystalloids to conventional IV fluids.  While widely used the problem with Normal Saline is that it has a chloride concentration significantly higher than that of human plasma. This can disrupt the body's acid-base balance, leading to hyperchloremic metabolic acidosis, a condition associated with renal vasoconstriction, reduced glome...
Post a Comment
Read more

ECPR- Basic Concepts

Extra-Corporeal Cardiopulmonary Resuscitation (ECPR) Introduction: What is ECPR? Extracorporeal Cardiopulmonary Resuscitation (ECPR) is an advanced resuscitative technique that utilizes extracorporeal membrane oxygenation (ECMO) to provide circulatory and respiratory support in patients experiencing refractory cardiac arrest. Unlike conventional cardiopulmonary resuscitation (CPR), which relies on chest compressions and ventilation, ECPR involves the rapid establishment of veno-arterial ECMO to maintain perfusion to vital organs while treating the underlying cause of cardiac arrest. ECPR is primarily used in specialized centers with well-trained personnel and appropriate infrastructure, making it a resource-intensive intervention. Background and History of ECPR The concept of extracorporeal circulation has been evolving since the early 1950s, with Dr. John Gibbon’s development of the first successful heart-lung machine. In the 1970s, the use of ECMO for neonates with respiratory failur...
Post a Comment
Read more